METTL3 inhibitor shows efficacy and synergy with venetoclax in preclinical models of AML

Dec. 29, 2023

Researchers from Epics Therapeutics SA presented preclinical data for EP-102, a novel small-molecule inhibitor of N6-adenosine-methyltransferase catalytic subunit (METTL3), being developed for the treatment of cancer.

BioWorld Science Conferences American Society of Hematology Cancer

Today's news in brief

BioWorld

BioWorld briefs for March 20, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 20, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...